Document:

Employment Agreement

 Exhibit 10.3 
 

 
 EMPLOYMENT AGREEMENT 

This Employment Agreement (the “Agreement”) is made as of May 9, 2011 (the “Effective Date”), between Patheon
Pharmaceuticals Services Inc. (the “Company”) and Michael Lytton (the “Executive”). 
 A. The Company is a
subsidiary of Patheon Inc. (“Patheon”). Patheon is in the business of providing its customers with pharmaceutical development services, clinical trial manufacturing and packaging, and commercial manufacturing and packaging. The Company
serves as the corporate shared services entity for Patheon and other members of the Patheon Group. As used herein, “Patheon Group” means Patheon and any entity controlled by Patheon. 

B. The Company and the Executive wish to enter into this Agreement to set forth the rights and obligations of each of them with respect
to the employment of the Executive. 
 C. The Company wishes to employ the Executive pursuant to the terms and subject to the
conditions set forth in this Agreement. 
 D. The Executive wishes to be employed by the Company pursuant to the terms and
subject to the conditions set forth in this Agreement. 
 E. The Company and the Executive agree that the terms, provisions and
mutual covenants of this Agreement suffice as adequate consideration for their mutual promises made in this Agreement. 
 NOW,
THEREFORE, the parties agree as follows: 
 ARTICLE 1 

INTERPRETATION 
  

	1.1	Governing Law. This Agreement shall be construed and interpreted in accordance with the substantive laws of the State of North Carolina, without giving
effect to any choice or conflict of law provision or rule (whether of the State of North Carolina or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the State of North Carolina. The state and
federal courts located in North Carolina shall be the exclusive forum for the adjudication of all disputes between the parties arising out of or relating to this Agreement. Each of the parties hereby irrevocably consents to the personal jurisdiction
of the federal and state courts in the State of North Carolina with respect to any matters arising out of this Agreement and waives any and all objections and defenses to such personal jurisdiction regardless of whether such objection or defense is
based upon the venue, North Carolina’s long-arm statute, residence and/or contacts with North Carolina, the convenience of the witnesses and/or parties, the inconvenience of the forum, or otherwise. 

 

	1.2	Definitions. In this Agreement, including Schedule A and B hereto, unless the context otherwise requires, the following terms shall have the following
meanings, respectively: 

  

	 	(a)	“Board of Directors” means the Board of Directors of Patheon. 

	 	(b)	“Cause” means the determination, in good faith, by the Company, after notice to the Executive that one or more of the following events has occurred:
(i) the Executive has failed to perform his material duties and, if curable, such failure has not been cured after a period of thirty (30) days’ notice from the Company; (ii) any reckless or grossly negligent act by the Executive
having the effect of injuring the interests, business, or reputation of any member of the Patheon Group in any material respect; (iii) the Executive’s commission of any felony (including entry of a nolo contendere plea);
(iv) any misappropriation or embezzlement of the property of any member of the Patheon Group; or (v) a breach of any material provision of this Agreement by the Executive, which breach, if curable, remains uncured for a period of thirty
(30) days after receipt by Executive of notice from the Company of such breach. 

  

	 	(c)	“Change in Control” means any of the following events: 

  

	 	(i)	Any “Person” (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)),
other than JLL Partners or its affiliates, becomes a Beneficial Owner (within the meaning of Exchange Act Rule 13d-3) of more than fifty percent (50%) of the voting power of the then outstanding voting securities of Patheon entitled to vote
generally in the election of directors; 

  

	 	(ii)	There is consummated a merger or consolidation of Patheon or any direct or indirect subsidiary of Patheon with any other company, other than a merger or consolidation
that would result in the voting securities of Patheon outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any
parent thereof) at least fifty percent (50%) of the combined voting power of the securities of Patheon or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation; or 

 

	 	(iii)	The shareholders of Patheon approve a plan of complete liquidation or dissolution of the company or there is consummated an agreement for the sale or disposition by
Patheon of all or substantially all of its assets. 

 However, in no event shall a “Change in Control” be
deemed to have occurred for purposes of this Agreement solely because Patheon (or any member of the Patheon Group) engages in an internal reorganization, which may include a transfer of assets to, or a merger or consolidation with, one or more
affiliates. 
  

	 	(d)	“Code” means the Internal Revenue Code of 1986, as amended. 

 

	 	(e)	 “Good Reason” means the occurrence of any of the following events without the consent of the Executive: (i) a material reduction
of the Executive’s duties or responsibilities or the assignment to the Executive of duties or responsibilities materially inconsistent with the Executive’s position; (ii) a material breach by the Company of this Agreement, which
breach remains uncured for a period of thirty (30) days after receipt by the Company of written notice from Executive (iii) a requirement by the Company that the Executive work more than fifty (50) miles from Executive’s
principle office. A termination of the Executive’s employment by Executive shall not be deemed to be for Good Reason unless (i) the Executive gives notice to the Company of the existence of the event or condition constituting Good
Reason within thirty (30) days after such event or condition 

	 	
initially occurs or exists, (ii) the Company fails to cure such event or condition within thirty (30) days after receiving such notice, and (iii) the Executive’s
“separation from service” within the meaning of Section 409A of the Code occurs not later than ninety (90) days after such event or condition initially occurs or exists. 

ARTICLE 2 

EFFECTIVE DATE; TERMS OF EMPLOYMENT 
  

	2.1	Term 

 The Company
hereby agrees to employ the Executive, and the Executive hereby agrees to be employed by the Company pursuant to the terms and subject to the conditions of this Agreement (including, without limitation, Article 6 and Schedules A and B), commencing
on the Effective Date. The Executive’s employment with the Company will be “at will,” meaning that either the Executive or the Company will be entitled to terminate the Executive’s employment at any time and for any reason, with
or without cause. Any contrary representations which may have been made to the Executive are superseded by this Agreement. This is the full and complete agreement between the Executive and the Company on this term. Although the Executive’s job
duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at will” nature of the Executive’s employment may only be changed in an express written
agreement signed by the Executive and a duly authorized officer of the Company. 
  

	2.2	Position and Duties 

The Executive shall be employed by the Company and shall serve as Executive Vice President, Corporate Development and Strategy and General
Counsel of Patheon, with such authority, duties and responsibilities as are commensurate with such position, reporting to the Chief Executive Officer. In addition, the Executive will be a member of the Patheon Group’s Executive Committee and
will become an officer of Patheon and of any members of the Patheon Group, as may be requested. 
 The Executive shall also be
responsible for the functions and responsibilities set out in the Position Description attached hereto as Schedule A. 
 The location of the Executive’s employment will be the Company’s Raleigh/Durham offices, located at 4721 Emperor Boulevard, Suite 200, Durham, North Carolina 27703, USA, or such other location
where the principal executive offices may be relocated from time to time by the Company. The Executive will be permitted to commute to the Company’s Raleigh/Durham offices from his primary residence in Boston, Massachusetts. The Executive will
be expected to be at the Company’s Raleigh/Durham offices or any other offices of the Company or otherwise engaged in the performance of his duties at least five days per week, subject to required business travel, vacation and holidays. In lieu
of Patheon’s standard relocation benefits, Executive will be entitled to a lump sum payment of $75,000 (subject to tax withholdings required by federal, state, and local laws). This amount will be treated as taxable income and will be paid
within thirty (30) days after the Effective Date (assuming the Executive continues to be employed by Patheon at such time). If the Executive’s employment is terminated other than (i) for Good Reason (as defined below) or
(ii) without Cause (as defined below) by the Company, before the first (1st) anniversary of the Effective Date, he will repay to the Company within thirty (30) days of the Date of Termination, a pro rata portion of the lump sum payment, based on the number of
months remaining to the first (1st) anniversary of
the Effective Date from the Date of Termination (by way of example, if the Date of Termination would occur with six (6) months remaining until the first (1st) anniversary of 

 
the Effective Date, then the Executive would repay fifty percent (50%) of the lump sum payment to the Company). The indicated repayment amount is not subject to offset or any other reduction
for any prior withholdings or deductions (i.e., tax withholdings). 
 In addition, a second lump sum payment
of $75,000 (subject to tax withholdings required by federal, state, and local laws) will be paid within thirty (30) days after the first (1st) anniversary of the Effective Date (assuming the Executive continues to be employed by Patheon at such time).
This amount will be treated as taxable income. If the Executive’s employment is terminated other than (i) for Good Reason (as defined below) by the Executive or (ii) without Cause (as defined below) by the Company, before the second
(2nd) anniversary of the Effective Date, he will
repay to the Company, within thirty (30) days of the Date of Termination, a pro rata portion of the second lump sum payment, based on the number of months remaining to the second
(2nd) anniversary of the Effective Date from the Date
of Termination (by way of example, if the Date of Termination would occur with six (6) months remaining until the second (2nd) anniversary of the Effective Date, then the Executive would repay fifty percent (50%) of the second lump
sum payment to the Company). The indicated repayment amount is not subject to offset or any other reduction for any prior withholdings or deductions (i.e., tax withholdings). 
 Notwithstanding the above, in the event that the Executive’s employment is terminated without Cause (as defined below) or terminated by the Executive for Good Reason (as defined below) at any time
during the six (6) month period following a Change in Control (as defined below), the lump sum payments will cease to be subject to the claw-back provisions, and the Executive will not be required to repay any portion thereof to the Company or
its successor. 
 Upon the Executive’s relocation to the Raleigh-Durham area in accordance with this Agreement, the
Executive will be entitled to a relocation package equal to no less than the then standard relocation package in North America for executives at the same level as the Executive in the Company, provided that any amount reimbursable thereunder will be
modified in a mutually agreeable manner, giving consideration to the total amount paid to the Executive pursuant to this Section 2.2. 
  

	2.3	Standards of Performance and Time Commitments 

 The Executive will, at all times, faithfully, industriously, and to the best of his ability, experience and talents, perform all of the duties required of and from him pursuant to the terms of this
Agreement. During the Executive’s employment, the Executive shall devote substantially all of his working time and attention to his duties with the Patheon Group and shall render no material business services to any other person or company;
provided, however, it shall not be a violation of this Agreement for the Executive, subject to the requirements of Article 6, to (a) to spend reasonable amounts of time to manage his personal, financial and legal affairs; (b) to fulfill
speaking engagements; and (c) with the Company’s consent, which will not be unreasonably withheld, to serve on civic, charitable, not-for-profit, industry or other for profit corporate boards, so long as such activities do not materially
interfere with the performance of the Executive’s duties or responsibilities under this Agreement. 

 ARTICLE 3 
 COMPENSATION AND BENEFITS 
  

	3.1	Base Salary 

 The
Company shall pay the Executive an annualized base salary (“Annual Base Salary”) at a rate of US$400,000, payable pursuant to the Company’s regular payroll practices for its executives in effect at the time. For fiscal year 2011, the
Executive’s Annual Base Salary will be prorated from the Effective Date. The Annual Base Salary shall be reviewed by the Chief Executive Officer, for increase only, at such time as the salaries of other senior executives of Patheon are reviewed
generally. 
  

	3.2	Executive Performance Bonus 

 The Executive shall be eligible to participate in an annual performance incentive plan under terms and conditions no less favorable than other senior executives of the Company; provided that the
Executive’s target bonus shall not be less than forty-five percent (45%) of his Annual Base Salary. The Executive’s payment under the annual performance incentive plan shall be based on meeting predetermined personal objectives and
Patheon’s financial performance. The personal objectives will be set by the Chief Executive Officer, and the financial performance measures will be set by the Chief Executive Officer. For fiscal year 2011, the annual performance bonus will be
prorated from the Effective Date. The annual performance bonus, if earned, will be paid to the Executive by the Company in the same manner and payment period generally applicable under the annual performance incentive plan and state law, but in no
event later than two and a half months after the later of (i) the end of the applicable performance period, or (ii) the end of the calendar year in which the performance period ends. Nothing contained in this Section 3.2 will
guarantee the Executive any specific amount of incentive compensation, or prevent the Chief Executive Officer from establishing performance goals and compensation targets applicable only to the Executive. 

 

	3.3	Stock Options 

  

	 	(a)	The Executive shall be eligible to participate in Patheon’s 2011 Amended and Restated Incentive Stock Option Plan (the “Stock Option Plan”) and shall be
eligible to be awarded options to acquire Patheon’s restricted voting shares from time to time in accordance with the terms of such Plan and related stock option award agreement (together, with the Stock Option Plan, the “Stock Option
Related Documents”). 

  

	 	(b)	Subject to approval of the Board of Directors at a meeting following the Effective Date, the Executive will be granted options to acquire four hundred thousand
(400,000) of Patheon’s restricted voting shares, which options shall be granted subject to the Stock Option Related Documents. Except as otherwise provided in the Stock Option Related Documents, the options will vest in five (5) equal
installments on each of the first five (5) anniversaries of the Effective Date, subject to the Executive’s continued employment with the Patheon Group until the relevant vesting dates . The subscription price for the shares under option
will be the market price (as defined in the Stock Option Plan) on the date of grant. All options granted to the Executive will expire ten (10) years from the date of grant. 

	 	(c)	During the Executive’s employment, at the discretion of the Board or its delegate, the Executive also will be eligible to receive additional options and other
long-term incentives under the Stock Option Plan or any similar plan adopted by Patheon from time to time in the course of its periodic review of executive compensation arrangements. 

 

	 	(d)	Upon the occurrence of a Change in Control, any options to purchase restricted voting shares of Patheon then held by the Executive shall, to the extent provided in the
applicable Stock Option Related Documents, become immediately vested and exercisable and remain exercisable for the remaining term of such option (which remaining term shall be determined without regard to the Executive’s termination of
employment). 

  

	 	(e)	The Executive will be required to comply with the Stock Option Related Documents and the terms of any share ownership guidelines of Patheon generally, as amended from
time to time. 

  

	3.4	Employee Benefits 

The Executive will be entitled to participate in all employee healthcare and welfare benefits programs of the Company, in accordance with
the then applicable terms, conditions and eligibility requirements of such programs that are offered from time to time to U.S. resident-based employees at the Executive’s level, including medical, dental, life insurance, 401-K retirement plans
and other health benefit programs. 
 In addition, the Executive will be entitled to four (4) weeks of vacation time,
subject to the Company’s vacation policy, as may be in effect from time to time, which will be pro-rated based on the Effective Date. Further, the Executive will be entitled to three (3) floating holidays annually and twenty-four
(24) hours for emergency time off annually, each in accordance with the Company’s policies, as may be in effect from time to time, and pro-rated for 2011 based on the Effective Date. 

 

	3.5	Reimbursement of Business Expenses 

 The Executive shall be reimbursed for all reasonable travel and other out-of-pocket expenses actually and properly incurred by the Executive during the Executive’s employment in connection with
carrying out his duties hereunder in accordance with the Company’s policies, as may be in effect from time to time. Notwithstanding the foregoing, the Executive shall not be entitled to any reimbursement under this Section 3.5 for any
commute to the Company’s Raleigh/Durham offices from his primary residence occurring prior to the second
(2nd) anniversary of the Effective Date. 

 

	3.6	Sarbanes-Oxley Act Loan Prohibition 

 To the extent that any Company or Patheon Group benefit, program, practice, arrangement or this Agreement would or might otherwise result in the Executive’s receipt of an illegal loan (the
“Loan”), the Company shall use commercially reasonable efforts to provide the Executive with a substitute for the Loan that is lawful and of at least equal value to the Executive. If this cannot be done, or if doing so would be
significantly more expensive to the Company than making the Loan, the Company need not make the Loan to the Executive or provide him a substitute for it. 

 ARTICLE 4 
 TERMINATION OF EMPLOYMENT 
  

	4.1	Death or Incapacity 

  

	 	(a)	The Executive’s employment shall be immediately terminated without notice by the Company upon the death of the Executive. 

 

	 	(b)	 If the Company determines in good faith that the Incapacity (as defined below) of the Executive has occurred during the Executive’s employment, it
may give to the Executive written notice in accordance with Section 7.4 of this Agreement of its intention to terminate the Executive’s employment; provided that such notice is provided no later than one hundred fifty (150) days
following the Executive’s first day of Incapacity. In such event, the Executive’s employment shall terminate effective on the thirtieth (30th) day after receipt of such notice by the Executive (the “Incapacity Effective Date”), provided that,
within such thirty (30) day period after such receipt, the Executive has not returned to full-time performance of the Executive’s duties. For purposes of this Agreement, “Incapacity” shall mean the failure of the Executive to
perform his duties under this Agreement for at least ninety (90) consecutive business days as a result of any medically determinable physical or mental impairment. The determination of Incapacity shall be made by a physician selected by the
Company or its insurers and reasonably acceptable to the Executive or the Executive’s legal representative. 

  

	4.2	Cause 

 The
Executive’s employment with the Company may be terminated with or without Cause. 
  

	4.3	Good Reason 

 The
Executive’s employment with the Company may be terminated by the Executive with or without Good Reason. 
  

	4.4	Notice of Termination 

 Any termination by the Company for Cause, or by the Executive for Good Reason, shall be communicated by Notice of Termination to the other party in accordance with Section 7.4. For purposes of this
Agreement, a “Notice of Termination” means a written notice which (a) indicates the specific termination provision in this Agreement relied upon, (b) to the extent applicable, sets forth in reasonable detail the facts and
circumstances claimed to provide a basis for termination of the Executive’s employment under the provision so indicated and (c) if the Date of Termination (as defined below) is other than the date of receipt of such notice, specifies the
termination date (which date shall be not more than 30 days after the giving of such notice). The failure by the Company or the Executive to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Cause or
Good Reason shall not waive any right of the Company or the Executive, respectively, hereunder or preclude the Company or the Executive, respectively, from asserting such fact or circumstance in enforcing the Company’s or the Executive’s
rights hereunder. 

	4.5	Date of Termination 

“Date of Termination” means (a) if the Executive’s employment is terminated by the Company for Cause, or by the
Executive for Good Reason, the date of receipt of the Notice of Termination or any later date specified therein, as the case may be, (b) if the Executive’s employment is terminated by the Company other than for Cause or Disability, the
Date of Termination shall be the date on which the Company notifies the Executive of such termination and (c) if the Executive’s employment is terminated by reason of death or Disability, the Date of Termination shall be the date of death
of the Executive or the Disability Effective Date, as the case may be. The Company and the Executive shall take all steps necessary (including with regard to any post-termination services by the Executive) to ensure that any termination described in
this Section 4.5 constitutes a “separation from service” within the meaning of Section 409A of the Code, and the date on which such separation from service takes place shall be the “Date of Termination.” 

 

	4.6	Resignation from All Positions 

 Notwithstanding any other provision of this Agreement, upon the termination of the Executive’s employment for any reason, unless otherwise requested by the Board of Directors, the Executive shall
immediately resign as of the Date of Termination from all positions that he holds or has ever held with the Patheon Group (and with any other entities with respect to which the Patheon Group has requested the Executive to perform services). The
Executive hereby agrees to execute any and all documentation to effectuate such resignations upon request by the Company, but he shall be treated for all purposes as having so resigned upon termination of his employment, regardless of when or
whether he executes any such documentation. 
 ARTICLE 5 

OBLIGATIONS OF THE COMPANY UPON TERMINATION 
  

	5.1	Good Reason; Other than for Cause  

 If the Company shall terminate the Executive’s employment other than for Cause, or if the Executive shall terminate the Executive’s employment for Good Reason: 

 

	 	(a)	The Company shall pay, or cause to be paid, to the Executive in a lump sum in cash the sum of: (i) that portion of the Executive’s Annual Base Salary earned
but not previously paid through the Date of Termination; (ii) reimbursement of expenses incurred on or before the Date of Termination in accordance with Section 3.5, above; and (iii) any accrued vacation pay, in each case to the
extent not theretofore paid (the sum of the amounts described in clauses (i), (ii), and (iii) shall be hereinafter referred to as the “Accrued Obligations”). The Accrued Obligations shall be paid on the regular payday following the
Date of Termination. 

  

	 	(b)	 Subject to Executive’s compliance with Section 5.3, Article 6 and Schedule B, the Company shall pay, or cause to be paid, to the Executive an
amount equal to the Executive’s Annual Base Salary, plus payment of any performance bonus set forth in Section 3.2 above for performance periods completed prior to the Date of Termination. Such amount shall generally be paid in cash in
twelve (12) equal monthly installments beginning within sixty (60) days after the Date of Termination or such later date set forth in Section 7.8. Notwithstanding the foregoing, if the severance benefit described in this
Section 5.1(b) exceeds two 

	 	
(2) times the lesser of (i) the Executive’s annual compensation or (ii) the compensation limit in effect under Section 401(a)(17) of the Code for the calendar year including
the Date of Termination, any amounts not yet paid as of the “short-term deferral date” shall be paid in a lump sum on the “short-term deferral date.” The “short-term deferral date” is the date that is two and one-half
months after the end of the later of (i) the calendar year containing the Date of Termination or (ii) the Company’s fiscal year containing the Date of Termination. 

 

	 	(c)	To the extent not theretofore paid or provided, Company (or Patheon, as the case may be) shall pay or provide, or cause to be paid or provided, to the Executive any
other amounts or benefits required to be paid or provided or which the Executive is eligible to receive under any plan, program, policy or practice or contract or agreement of the Patheon Group (such other amounts and benefits shall be hereinafter
referred to as the “Other Benefits”), in accordance with the terms and normal procedures of each such plan, program, policy or practice or contract or agreement, based on earned, accrued or vested benefits through the Date of Termination.

 If the Executive receives payments and benefits pursuant to this Section 5.1, then the
Executive shall not be entitled to any other severance pay or benefits under any severance plan, program or policy of any member of the Patheon Group, unless otherwise specifically provided therein in a specific reference to this Agreement;
provided, however, in the event any payment is made, or required to be made, under any such severance plan, program or policy, then the amounts payable under this Section 5.1 shall be reduced by such amount. 

 

	5.2	Death or Incapacity; Cause; Other than for Good Reason 

 If the Executive’s employment is terminated due to death or Incapacity or for Cause, or if the Executive voluntarily terminates his employment without Good Reason, this Agreement shall terminate
without further obligations to the Executive other than the obligation to pay to the Executive his Accrued Obligations through the Date of Termination and the Other Benefits earned, accrued, or vested through the Date of Termination, in each case to
the extent not theretofore paid or provided. All Accrued Obligations shall be paid to the Executive in accordance with Section 5.1(a) and the Other Benefits shall be paid to the Executive in accordance with Section 5.1(c). The Company (and
the Patheon Group) will have no further obligation to pay any compensation of any kind (including, without limitation, any bonus or portion of a bonus that otherwise may have become due and payable to the Executive with respect to the year in which
such Date of Termination occurs), or severance payment of any kind, nor will the Company (or the Patheon Group) have any obligation to make any payment in lieu of notice. 

 

	5.3	Release 

Notwithstanding anything contained herein to the contrary, the Company shall only be obligated to make the payments under
Section 5.1(b) if, in addition to the other contingencies under Section 5.1(b): (a) within the 50-day period after the Date of Termination, the Executive executes a general release, in a form provided by the Company, of all current or
future claims, known or unknown, against the Patheon Group, its officers, directors, shareholders, employees and agents arising on or before the date of the release, including but not limited to all claims arising out of the Executive’s
employment with the Patheon Group or the termination of such employment, and (b) the Executive does not revoke the release during the seven-day revocation period 

 
prescribed by the Age Discrimination in Employment Act of 1967, as amended, or any similar revocation period, if applicable. The Company shall be obligated to provide such release to the
Executive promptly following the Date of Termination. 
 ARTICLE 6 

RESTRICTIVE COVENANTS 
  

	6.1	In General 

  

	 	(a)	The Executive acknowledges and agrees that the Patheon Group is a business engaged in the sale of commercial pharmaceutical manufacturing capabilities and/or
pharmaceutical development services, and during the Executive’s employment, the Patheon Group’s business may expand or change (“the Patheon Group’s Business”). Any such expansions and changes shall expand or change the
Executive’s obligations under this Agreement accordingly. The Patheon Group’s Business is international in scope and without geographical limitation and the Patheon Group has valuable business relationships within its industry throughout
the world. 

  

	 	(b)	By virtue of the Executive’s employment by and position with the Company: (i) the Executive has or will have access to confidential and proprietary
information of the Patheon Group, including valuable information about its business operations and methods and the persons with whom it does business in various locations throughout the world that is not generally known to, or readily ascertainable
by, the Patheon Group’s competitors, and the Executive understands that the continued success of the Patheon Group depends upon the use and protection of a large body of confidential and proprietary information, and (ii) the Executive has
specialized knowledge of, and has received or will receive specialized training in, the Patheon Group’s Business. 

  

	 	(c)	The Executive authorizes the Company to disclose this Agreement to Executive’s future or prospective employers along with notification of the Company’s intent
to exercise all rights it has to seek enforcement of its terms. 

  

	6.2	Confidentiality Undertaking 

 The Executive confirms that he is bound by the provisions of the Confidentiality Undertaking covenant set out in Schedule B hereto. 

 

	6.3	Non-Compete, Non-Solicitation  

  

	 	(a)	During the Executive’s employment with the Company and for one (1) year thereafter (the “Non-compete Period”), the Executive shall not engage in any
of the following activities (except in connection with his/her duties for the Company): 

  

	 	(i)	engage in any business activity that competes with the Patheon Group’s Business within the geographical areas set forth in Section 6.3(b);

  

	 	(ii)	 within the geographical areas set forth in Section 6.3(b), solicit or do business which is the same, similar to or otherwise in competition with
the business engaged in by the Patheon Group, from or with persons or entities: (a) who are customers of the Patheon Group; (b) whom Executive or someone for whom Executive was responsible solicited, negotiated, contracted, serviced or had
contact with on the Patheon Group’s behalf; (c) who were customers of the Patheon Group at any time 

	 	
during the last year of the Executive’s employment with the Patheon Group; or (d) to whom the Patheon Group had made proposals to do business at any time during the last year of the
Executive’s employment with the Company; or 

  

	 	(iii)	offer employment to or otherwise solicit for employment any employee or other person who had been employed by the Patheon Group during the last year of the
Executive’s employment with the Company; 

  

	 	(iv)	within the geographical areas set forth in Section 6.3(b), be employed (or otherwise engaged) in (i) a management capacity, (ii) other capacity providing
the same or similar services which the Executive provided to the Patheon Group, or (iii) any capacity connected with competitive business activities, by any person or entity that engages in the same, similar or otherwise competitive business as
the Patheon Group; 

  

	 	(v)	directly or indirectly take any action which is materially detrimental or otherwise intended to be adverse to the Patheon Group’s goodwill, name, business
relations, prospects and operations. 

  

	 	(b)	The restrictions set forth in this Section 6.3 apply to the following geographical areas: (i) the Research Triangle Park, North Carolina metropolitan area;
(ii) the Cincinnati, Ohio metropolitan area; (iii) any city, metropolitan area, county (or similar political subdivisions in foreign countries) in which the Patheon Group is located or does or, during the Executive’s employment with
the Company, did business; (iv) any city, metropolitan area, county (or similar political subdivisions in foreign countries) in which the Executive’s services were provided, or for which the Executive had responsibility, or in which the
Executive worked on Patheon Group projects, while employed by the Company. 

  

	 	(c)	If, at the time of enforcement of this Section 6.3, a court holds that the restrictions stated herein are unreasonable under circumstances then existing, the
Executive agrees that they be “blue-penciled” or rewritten by the court to the extent necessary to render them enforceable. In addition, the one (1) year time period specified in this Section 6.3 shall be tolled and shall not run
during any time the Executive is in violation of Section 6.3 or period(s) of time required for legal action to enforce the provisions of this Section 6.3. 

 

	6.4	Remedies 

 Because
the Executive has access to Confidential Information (as defined in Schedule B), the Executive understands and agrees the Patheon Group would suffer irreparable harm from a breach of this Agreement and that money damages would not be an adequate
remedy for any such breach of this Agreement. Therefore, in the event of a breach or threatened breach of this Agreement (including Schedules A and B), the Patheon Group and its successors or assigns, in addition to other rights and remedies
existing in their favor, shall be entitled to specific performance and/or injunctive or other equitable relief from a court of competent jurisdiction in order to enforce, or prevent any violations of, the provisions hereof (without posting a bond or
other security) as well as court costs and reasonable attorney’s fees. 

	6.5	Acknowledgements 

The Executive agrees and acknowledges that the promises and obligations made by the Company in this Agreement (specifically including, but
not limited to, the payments and benefits provided for under Section 5.1(b) and (d) hereof) constitute sufficient consideration for the covenants contained in this Article 6 and Schedule B. The Executive further acknowledges that it is not
the Patheon Group’s intention to interfere in any way with his employment opportunities, except in such situations where the same conflict with the legitimate business interests of the Patheon Group. The Executive agrees that he will notify the
Company in writing if he has, or reasonably should have, any questions regarding the applicability of this Article 6 and Schedule B. 
  

	6.6	Survival 

 Subject
to any limits on applicability contained therein, this Article 6 and Schedule B shall survive and continue in full force in accordance with their respective terms, notwithstanding any expiration or termination of this Agreement. 

ARTICLE 7 

GENERAL PROVISIONS 
  

	7.1	Entire Agreement 

This Agreement, together with Schedules A and B attached hereto and incorporated herein by reference, when executed by both parties shall
constitute the entire agreement pertaining to the Executive’s employment and supersedes all prior agreements, understandings, negotiations and discussions, whether written or oral, pertaining to the Executive’s employment, and there are no
representations, undertakings or agreements of any kind between the parties respecting the subject matter hereof except those contained herein. The recitals set forth above are incorporated herein by this reference with the same force and effect as
if set forth herein as agreements of the parties. This Agreement supersedes the offer letter between the parties, dated April 18, 2011. 
  

	7.2	Severability 

 If
any provision of this Agreement is declared void or unenforceable, such provision shall be deemed severed from this Agreement to the extent of the particular circumstances giving rise to such declaration and such provision as it applies to other
persons and circumstances and the remaining terms and conditions of this Agreement shall remain in full force and effect. 
  

	7.3	Representations 

The Executive represents and warrants that (a) he is not a party to any contract, understanding, agreement or policy, whether or not
written, with his current employer (or any previous employer) or otherwise, that would be breached by the Executive’s entering into, or performing services under, this Agreement and (b) will not knowingly use any trade secret, confidential
information, or other intellectual property right of any other party in the performance of his duties hereunder. The Executive will indemnify, defend, and hold each member of the Patheon Group harmless, from any and all suits and claims arising out
of any breach of such restrictive contracts, understandings, agreements or policies. 

	7.4	Notices 

 All
notices and other communications hereunder shall be in writing and shall be given by hand delivery to the other party or by registered or certified mail, return receipt requested, postage prepaid, addressed as follows: 

If to the Executive: 
 Mr. Michael Lytton 
 48 Conant Road 

Lincoln, MA 01773 

If to the Company: 
 Patheon Pharmaceutical Services Inc. 
 4721 Emperor Blvd., Suite 200 

Durham, NC 27703 

Attention: Senior Human Resources Executive 
 with a copy to: 
 Patheon Pharmaceutical Services Inc. 

4721 Emperor Blvd., Suite 200 
 Durham, NC 27703 
 Attention: Legal Department 

or to such other address as either party shall have furnished to the other in writing in accordance herewith. Notice and communications
shall be effective when actually received by the addressee. 
  

	7.5	Withholding 

 The
Company may withhold from any compensation and benefits payable under this Agreement all federal, state, city and other taxes or amounts as shall be determined by the Company to be required to be withheld pursuant to applicable laws, or governmental
regulations or rulings. The Executive shall be solely responsible for the satisfaction of any taxes (including employment taxes) imposed on employees and penalty taxes on nonqualified deferred compensation. 

 

	7.6	Waiver 

 The
Executive’s or the Company’s failure to insist upon strict compliance with any provision of this Agreement or the failure to assert any right the Executive or the Company may have hereunder, including, without limitation, the right of the
Executive to terminate employment for Good Reason, shall not be deemed to be a waiver of such provision or right or any other provision or right of this Agreement. 
  

	7.7	Successors 

  

	 	(a)	 This Agreement is personal to the Executive is not assignable by the Executive. This Agreement shall inure to the benefit of and be enforceable by the
Executive’s legal representatives. This Agreement shall inure to the benefit of 

	 	
and be binding upon the Company, the other members of the Patheon Group, and their respective successors and assigns. 

 

	 	(b)	The Company, at its discretion, may assign this Agreement, and will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise)
to all or substantially all of the business and/or assets of Patheon or the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession
had taken place. 

  

	7.8	Compliance with Section 409A of the Code 

  

	 	(a)	Although the payments and benefits provided under this Agreement are intended to be exempt from the application of, or otherwise comply with, the requirements of
Section 409A of the Code (“Section 409A”), the tax treatment of the payments and benefits provided under this Agreement is not warranted or guaranteed. Specifically, any taxable benefits or payments provided under this Agreement are
intended to be separate payments that qualify for the “short-term deferral” exception to Section 409A to the maximum extent possible, and to the extent they do not so qualify, are intended to qualify for the involuntary separation pay
exceptions to Section 409A to the maximum extent possible. This Agreement shall be construed, administered, and governed in a manner that effects such intent, and the Company shall not take any action that would be inconsistent with such
intent. Without limiting the foregoing, the payments and benefits provided under this Agreement may not be deferred, accelerated, extended, paid out or modified in a manner that would result in the imposition of an additional tax under
Section 409A upon the Executive. 

  

	 	(b)	If neither the “short-term deferral” nor the involuntary separation pay exceptions to Section 409A described above applies to a benefit, payment or
reimbursement under this Agreement, then notwithstanding any provision herein to the contrary, the remaining provisions of this Section 7.8(b) shall apply. 

 

	 	(i)	 If the Executive is a “specified employee,” as determined under the Company’s policy for identifying specified employees on the Date of
Termination, then to the extent required in order to comply with Section 409A, all payments and benefits provided under this Agreement that constitute a “deferral of compensation” within the meaning of Section 409A, that are
provided as a result of a “separation from service” within the meaning of Section 409A and that would otherwise be paid or provided during the first six months following such Date of Termination shall be accumulated through and paid
or provided (together with interest on the delayed amount at the applicable federal rate under Section 7872(f)(2)(A) of the Code in effect on the Date of Termination) within thirty (30) days after the first business day following the sixth
(6th) month anniversary of such Date of Termination
(or, if the Executive dies during such six-(6-)month period, then within thirty (30) days after the Executive’s death). 

  

	 	(ii)	 To the extent required by Section 409A, each reimbursement or in-kind benefit provided under this Agreement that will not be excluded from
Executive’s income when received is subject to the following requirements: (i) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during each calendar year can not affect the

	 	
expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year; (ii) any reimbursement of an eligible expense shall be made on or before the last day of
the calendar year following the calendar year in which the expense was incurred; and (iii) the right to reimbursements or in-kind benefits under this Agreement shall not be subject to liquidation or exchange for another benefit.

  

	 	(c)	Although the Company will endeavor to avoid the imposition of taxation, interest and penalties under Section 409A of the Code, the tax treatment of the benefits
provided under this Agreement is not warranted or guaranteed. Neither the Patheon Group nor its directors, officers, employees or advisers shall be held liable for any taxes, interest, penalties or other monetary amounts owed by the Executive or
other taxpayer as a result of the Agreement. Any reference in this Agreement to Section 409A of the Code will also include any proposed, temporary or final regulations, or any other guidance, promulgated with respect to such
Section 409A by the U.S. Department of Treasury or the Internal Revenue Service. 

 NOW THEREFORE, the
parties below have entered into this Agreement as of the date first written above. 
  

			
	PATHEON PHARMACEUTICALS SERVICES INC.
		
	By:	 	/s/ James C. Mullen
	Name:	 	James C. Mullen
	Title:	 	Chief Executive Officer

  

					
		 		 	EXECUTIVE
			
	SIGNED, SEALED AND DELIVERED	 	)	 	
	 in the presence of
	 	)	 	
		 	)	 	
	/s/ Meghan Lytton	 	)	 	/s/ Michael Lytton
	Name of Witness:	 		 	 Michael Lytton

 

 
 SCHEDULE A 
 TO 
 EMPLOYMENT AGREEMENT WITH 

Michael Lytton 
  

POSITION DESCRIPTION 
 The functions and responsibilities of the Executive Vice President, Corporate Development and Strategy and General Counsel will include the following: 

 

	 	A.	SCOPE AND GENERAL RESPONSIBILITIES: 

  

	 	•	 	 Span of control involves executive leadership of Patheon’s international operations and global customers. 

 

	 	•	 	 Ensures compliance with securities laws, issues for debt, equities and mixed financial instruments. 

 

	 	•	 	 Develops and negotiates complex business arrangements including short-term and long-term business contracts with complex provisions.

  

	 	•	 	 Leads and coordinates corporate development activities, such as mergers and acquisitions, licensing, divestments, joint ventures, strategic alliances
(outside of core Sales and Marketing activities) and similar business arrangements. 

  

	 	•	 	 Leads strategic planning activities. 

  

	 	•	 	 Leads and/or directs global litigation, including but not limited to, business contracts, performance issues and employment charges or litigation.

  

	 	•	 	 Ensures compliance with regulatory legal matters including the activities of international bodies such as the FDA, US DEA, EMEA, EPA, etc.

  

	 	•	 	 Supports manufacturing activities requiring filings and registration with these regulators covering environmental, safety, employment conditions, etc.

  

	 	•	 	 Provides direction in matters involving intellectual property laws with respect to pharmaceutical products, formulations, manufacturing processes and
devices that affect many of the products and customers. 

  

	 	B.	MANAGEMENT: 

  

	 	•	 	 Provides material support for execution of global Legal and Corporate Development responsibilities to protect and support sustained growth of the
business and improve profitability. 

	 	•	 	 Provides executive leadership to the global Legal and Corporate Development functions, including management of a diverse Legal team located in several
countries where Patheon conducts its Commercial and Development business. 

  

	 	C.	ETHICS, CULTURE, POLICY & PUBLIC REPRESENTATION: 

 Ensures global employees comply with company established Ethics, Confidentiality and other practices including but not limited to Patheon’s Code of Business Conduct or other country specific
policies. 
 This position description is not intended as a complete list of all responsibilities and responsibilities may change.

 

 
 SCHEDULE B 
 TO 
 EMPLOYMENT AGREEMENT WITH 

Michael Lytton 
  

CONFIDENTIALITY, INVENTIONS ASSIGNMENT AND RETURN OF PROPERTY 

UNDERTAKING 
 In
consideration of Michael Lytton (the “Executive”) accepting an employment agreement between the Executive and Patheon Pharmaceuticals Services Inc. (the “Company”) dated May 9, 2011, (the “Agreement”) to which this
Confidentiality, Inventions Assignment and Return of Property Undertaking (“Confidentiality Undertaking”) is attached as Schedule B, the Executive undertakes and covenants with the Patheon Group (as defined in the Agreement) as follows:

  

	1.	CONFIDENTIAL INFORMATION 

Executive acknowledges that all Confidential Information (defined below) is the sole and exclusive property of the Patheon Group (or a
third party providing such information to the Patheon Group). At all times during Executive’s employment and thereafter, Executive will hold in strictest confidence and will not use, disclose, copy or remove from the Patheon Group premises any
Confidential Information, nor aid third parties in obtaining or using any Confidential Information, nor access or attempt to access any Patheon Group computer systems, networks or any resources or data that resides thereon, except as such
use, disclosure, copying, removal or access may be required in connection with Executive’s employment and only then in accordance with applicable Patheon Group policies and procedures and solely for the Patheon Group’s benefit.
Executive further acknowledges that the applicable Patheon Group policies and procedures referenced in the preceding sentence include but are not limited to the following and apply regardless of whether or not the information is Confidential
Information: (i) no forwarding of electronic files, data, emails or other information to home, personal or external email accounts even for the purpose of working remotely; (ii) no use of thumb drives, flash drives or other portable
devices or copying methods without the express written consent of the Company; (iii) no copying of hard copy documents for removal from the worksite even for the purpose of working remotely; (iv) emails, voicemails or other communications,
whether written, verbal, electronic or otherwise, sent to Executive are for his/her eyes/ears only and are not to be shared with any other employee or person, except with the express consent of the sender; and (v) violation of policies and
procedures regarding Patheon Group information is grounds for immediate termination for Cause. Additionally, Executive will notify the Patheon Group of any known or suspected unauthorized use, disclosure, copying or removal of Confidential
Information by others. 
 As used in this Agreement, “Confidential Information” means any and all facts, data or
information of the Patheon Group (or of third parties providing such information to the Patheon Group) that is not known by, or generally available to the public at large, that concerns the business of the Patheon Group (or third parties providing
such information to the Patheon Group) whether now existing or to be developed in the future, and whether embodied in tangible or intangible form or merely remembered, including but not limited to trade secrets or

 
other intellectual property; products, product plans, designs, ideas, concepts, costs, methods or policies; prices or price formulas; processes; procedures; raw materials; research, development
or know-how; customer lists and information, information relating to customers, prospective partners, partners, parents, subsidiaries, affiliates and other entities; financial information; computer software (including design, programming techniques,
flow charts, source code, object code, and related information and documentation); products and services; inventory lists; market and/or product research and development data; business strategies and methodologies, strategic or business plans,
training manuals and methodologies; employee phone and address lists, personnel data, incentive packages, compensation data and employee performance data; and all other information of any kind or character relating to the development, improvement,
manufacture, sale, or delivery of products or services by the Patheon Group. 
 If Executive is required to disclose
Confidential Information pursuant to a court order or such disclosure is necessary to comply with applicable law or defend against claims, Executive shall: (i) notify the Patheon promptly before any such disclosure is made; (ii) at
Patheon’s request and expense take all reasonably necessary steps to defend against such disclosure, including defending against the enforcement of the court order, other government process or claims; and (iii) permit the Patheon Group to
participate with counsel of its choice in any related proceeding. 
  

	2.	INVENTIONS 

  

	 	a.	Inventions. Subject to paragraph 2 b., Executive agrees that all right, title, and interest in and to (i) all discoveries, designs, ideas, works of
authorship, and inventions created, conceived, reduced to practice, or otherwise developed, in whole or in part, by Executive, whether jointly or individually, during Executive’s employment or within three years following termination of
employment for any reason whatsoever; (ii) all improvements, modifications, and derivative works to and of any of the foregoing in (i); and (iii) all patent, copyright, trademark, trade secret and other intellectual property rights in any
of the foregoing in (i) and (ii) (all the foregoing in (i)-(iii), collectively, the “Inventions”) will be owned solely and exclusively by the Company. Without limiting the foregoing, all copyrightable subject matter included in
the Inventions shall constitute “work made for hire” under applicable copyright law. Executive will: 

  

	 	(i)	promptly and fully disclose and describe, in detail satisfactory to the Company, all such Inventions in writing to the Company; 

 

	 	(ii)	irrevocably and unconditionally assign, and Executive does hereby irrevocably and unconditionally assign, to the Company, without further compensation or other
consideration, any and all of Executive’s rights, title and interest in and to the Inventions, including without limitation (1) all rights to collect royalties for any use, and pursue remedies for any infringement, misappropriation, or
other violation, thereof and (2) all applications for letters of patent, copyright registrations, trademark, service mark, and trade dress registrations, and industrial design or other forms of protection granted for the Inventions throughout
the world; 

  

	 	(iii)	 deliver promptly to the Company, upon request and in the form and manner prescribed by the Company (without charge to the Company but at the
Company’s expense), including without limitation Executive’s notarized signature in execution of, the written instruments described in paragraph b. and perform all other acts deemed necessary by the

	 	
Company to obtain and maintain the instruments and to transfer all rights and title thereto to the Company in accordance with this Agreement; and 

 

	 	(iv)	promptly render all assistance that may be required by the Company to enable it to protect or exploit the Inventions in any country of the world.

 In addition, Executive does hereby waive and agree never to assert any rights in the Inventions, and any part or
parts thereof, that are not susceptible of assignment by Executive under applicable law, including, but not limited to, any moral rights or the right to the integrity or attribution of the Inventions, or any other right to be associated with the
Inventions as its author, inventor, or user by name or under a pseudonym or the right to remain anonymous. 
  

	 	b.	Excluded Inventions. The provisions of paragraph 2 a. will not apply to Inventions which fulfill all of the following criteria: 

 

	 	(i)	Inventions for which no equipment, supplies, facility or Confidential Information belonging to the Company were used; and 

 

	 	(ii)	Inventions that do not relate to the business of the Company or to the Company’s actual or demonstrably anticipated processes, research or development; and

  

	 	(iii)	Inventions that do not result from any work performed by Executive for the Company. 

 

	3.	RETURN OF COMPANY PROPERTY 

Upon the Company’s request and, in any event, upon the cessation of Executive’s employment with the Company, Executive will
return to the Company all Confidential Information in Executive’s possession or control, along with all Company property, including but not limited to keys, pass cards, identification cards, computer hardware and software, manuals, passwords,
customer lists, sales records, business plans, any data concerning customers of the Company, brochures of the Company and of any competitor, all corporate records, policy handbooks, receipts, documents, records, files and other documents in whatever
form they exist, whether electronic, hard copy or otherwise, and all copies, notes or summaries thereof. Any and all such documents contained on Executive’s personal computer or devices shall be printed, delivered to the Company and
thereafter deleted from the personal computer/device. These documents and items must be returned whether in Executive’s possession, work area, home, vehicle or in the wrongful possession of any third party with Executive’s knowledge or
acquiescence, and whether prepared by the Company or any other person or entity. 

 I HAVE READ THIS AGREEMENT CAREFULLY AND UNDERSTAND ITS TERMS. 

 

							
	/s/ Michael Lytton	 	(SEAL)	 		 	5/9/11
	Executive’s Signature	 		 		 	Date:
				
	Michael Lytton	 		 		 	 
	Print Executive Name	 		 		 	

 The signature above was witnessed by: 
  

							
	/s/ Meghan Lytton	 		 		 	5-9-11
	Witness’ Signature	 		 		 	Date:
				
	Meghan Lytton	 		 		 	 
	Witness’ NameSecond Amendment to Credit Agreement

 Exhibit 10(a) 
 SECOND AMENDMENT TO CREDIT AGREEMENT 
 THIS SECOND AMENDMENT TO CREDIT
AGREEMENT, dated as of September 2, 2011 but effective as of August 31, 2011 upon the satisfaction of the conditions in Article 4 (this “Amendment”), is by and between NEOGEN CORPORATION, a Michigan corporation (the
“Borrower”), and JPMORGAN CHASE BANK, N.A., a national banking association (the “Bank”), acting through its Lansing Business Banking LPO. 
 RECITALS 
 A. The Borrower and the Bank have entered into that certain
Credit Agreement dated as of May 20, 2010, as amended by First Amendment to Credit Agreement dated as of September 24, 2010 (as amended, the “Credit Agreement”). 

B. The Borrower and the Bank desire to amend the Credit Agreement on the terms and conditions set forth in this Amendment. 

NOW, THEREFORE, in consideration of the premises and of the mutual agreements herein contained, the parties hereto agree as follows:

 ARTICLE 1. AMENDMENT TO CREDIT AGREEMENT 

Subject to Article 2 of this Amendment, the Credit Agreement hereby is amended as follows: 

1.1 Section 1.2 of the Credit Agreement is amended and restated as follows: 

 

	 	1.2	 Facility A (Line of Credit). The Bank has approved a credit facility to the Borrower in the principal sum not to exceed, in the aggregate at any
one time outstanding, the remainder of (a) $10,000,000.00 minus (b) the Letter of Credit Liabilities (as defined below) at such time (such credit facility herein referred to as “Facility A”). Credit under Facility A shall be
repayable as set forth in a Line of Credit Note dated the date hereof or the date of any amendment hereof, as the case may be, and any renewals, modifications, extensions, rearrangements and restatements thereof and replacements or substitutions
therefor. The Bank, or any affiliate of the Bank, may from time to time in its sole discretion, prior to the maturity date of the Note evidencing Facility A, as renewed, modified, extended or restated from time to time, and including any
replacements or substitutions therefor (the “Facility A Note”), issue one or more letters of credit (each a “Letter of Credit”) for the account of the Borrower. Each Letter of Credit shall be issued based upon an Application and
Agreement for Standby/Commercial Letter of Credit (each an “Application”), in form and substance as reasonably and customarily required by the Bank, which Application shall be executed by the Borrower. The Borrower agrees to pay the Bank
all fees and expenses associated with each Application. Pursuant to the applicable Application, each funding under a Letter of Credit shall be reimbursed by the Borrower upon demand. Unless otherwise agreed by the Bank in its

	 	
sole discretion, each Letter of Credit shall have an expiration date that does not exceed the scheduled maturity date of the Facility A Note. Notwithstanding anything to the contrary, the maximum
aggregate amount of the unfunded commitments plus any unpaid reimbursements with respect to all Letters of Credit (collectively, the “Letter of Credit Liabilities”) shall not at any time exceed $2,000,000. Whenever a Default has occurred
and is continuing, or upon the occurrence of the date that is five (5) Business Days (as defined in the Facility A Note) prior to the scheduled maturity date of the Facility A Note, immediately upon demand by the Bank the Borrower shall provide
cash collateral to the Bank for the Letter of Credit Liabilities in the aggregate amount of the Letter of Credit Liabilities at such time. The Borrower will use the proceeds of the loans under Facility A and the Letters of Credit for its general
corporate purposes. 

 1.2 Section 1.3 is added to the Credit Agreement as follows: 

 

	 	1.3	Facility B (Line of Credit). The Bank has approved a credit facility to the Borrower in the principal sum not to exceed, in the aggregate at any one time
outstanding, $2,000,000.00 (such credit facility herein referred to as “Facility B”). Credit under Facility B shall be repayable as set forth in a Line of Credit Note dated the date hereof or the date of any amendment hereof, as the case
may be, and any renewals, modifications, extensions, rearrangements and restatements thereof and replacements or substitutions therefor (the “Facility B Note”). The Borrower will use the proceeds of the loans under Facility B to make, and
only to make, payment of any and all obligations of the Borrower under or in respect of Rate Management Transactions when due. Unless the Borrower shall have made each such payment to the Bank immediately when due, the Bank shall be deemed to have
disbursed to the Borrower, and the Borrower shall be deemed to have elected to satisfy such payment obligation by, a loan under Facility B in an amount equal to the amount of such payment obligation. Such loan under Facility B shall be disbursed (in
satisfaction of such payment obligation) notwithstanding any failure to satisfy any conditions for disbursement of any loan set forth in this agreement and, to the extent of the loan under Facility B so disbursed, the corresponding obligation of the
Borrower or its Subsidiary under or in respect of a Rate Management Transaction shall be deemed satisfied; provided, however, that nothing in this Section 1.3 shall be deemed to constitute a waiver of any Default caused by the
failure to satisfy the conditions for disbursement or otherwise. If, for any reason (including without limitation as a result of the occurrence of a Default with respect to the Borrower pursuant to Section 7.1F., G., H. or I.), loans may not be
made by the Bank under Facility B, then the Borrower agrees that each payment obligation under or in respect of Rate Management Obligations not paid pursuant to the disbursement of a loan under Facility B shall bear interest, payable on demand by
the Bank, at the interest rate or rates, including any rate applicable in the event of Default, applicable from time to time under the Facility B Note. 

  
 [Second
Amendment to Credit Agreement – Neogen Corporation] 
 -2- 

 ARTICLE 2. CONDITIONS PRECEDENT 

As conditions precedent to the effectiveness of the amendment to the Credit Agreement set forth in Article 1 of this Amendment, the Bank
shall receive the following documents and the following matters shall be completed, all in form and substance satisfactory to the Bank: 
 2.1 This Amendment duly executed on behalf of the Borrower and the Bank. 
 2.2 A
replacement Line of Credit Note in the principal amount of $10,000,000 evidencing Facility A (the “Replacement Facility A Note”), duly executed on behalf of the Borrower. 

2.3 A Line of Credit Note in the principal amount of $2,000,000 evidencing Facility B (the “Facility B Note” and, with the
“Replacement Facility A Note”, collectively, the “New Notes” and, individually, a “New Note”), duly executed on behalf of the Borrower. 
 2.4 A certificate of the Chief Financial Officer of the Borrower to the effect that there are no new or additional material commitments or contingent liabilities or other obligations of the Borrower since
May 31, 2011 and no material adverse developments in any commitments or contingent liabilities or other obligations of the Borrower previously identified in the Borrower’s annual financial statement as of, and for the fiscal year ended,
May 31, 2011. 
 2.5 An updated opinion letter of counsel for the Borrower, substantially in the form of the opinion letter
of counsel for the Borrower delivered to the Bank in connection with the Credit Agreement, covering this Amendment, the New Notes, the transactions contemplated by this Amendment and the other matters covered in such prior opinion letter.

 2.6 Such other documents, and completion of such other matters, as the Bank may reasonably deem necessary or appropriate to
carry out the intent of, and/or implement, this Amendment. 
 ARTICLE 3. REPRESENTATIONS AND WARRANTIES 

In order to induce the Bank to enter into this Amendment, the Borrower represents and warrants that: 

3.1 The execution, delivery and performance by the Borrower of this Amendment and the New Notes are within its corporate powers, have
been duly authorized by all necessary corporate action and are not in contravention of any applicable law, rule or regulation, or any applicable judgment, decree, writ, injunction, order or award of any arbitrator, court or governmental authority,
or of the terms of the Borrower’s charter or by-laws, or of any contract or undertaking to which the Borrower is a party or by which the Borrower or its property is or may be bound or affected. 

3.2 This Amendment is, and each of the New Notes when delivered hereunder will be, a legal, valid and binding obligation of the Borrower,
enforceable against the Borrower in accordance with its respective terms, except as may be limited by bankruptcy, insolvency or other laws affecting the enforcement of creditors’ rights generally and by general principles of equity. 

3.3 No consent, approval or authorization of or declaration, registration or filing with any governmental or nongovernmental person or
entity, including without limitation any creditor, stockholder or lessor of the Borrower, remains required on the part of the Borrower in connection with the execution, delivery and performance of this Amendment or the New Notes or the transactions
contemplated hereby or as a condition to the legality, validity or enforceability of this Amendment or the New Notes. 

  
 [Second
Amendment to Credit Agreement – Neogen Corporation] 
 -3- 

 3.4 After giving effect to the amendments contained in Article 1 of this Amendment, the
representations and warranties contained in Section 6 of the Credit Agreement and in the other Related Documents are true on and as of the date hereof with the same force and effect as if made on and as of the date hereof. No default has
occurred and is continuing under the Credit Agreement, the Notes or any of the other Related Documents. 
 ARTICLE 4.
MISCELLANEOUS 
 4.1 If the Borrower shall fail to perform or observe any term, covenant or agreement in this Amendment,
or any representation or warranty made by the Borrower in this Amendment shall prove to have been incorrect in any material respect when made, such occurrence shall be deemed to constitute an event of default under the Credit Agreement and the
Notes. 
 4.2 All references to the Credit Agreement in the Notes, any other Related Documents or any other document, instrument
or certificate referred to in the Credit Agreement or delivered in connection therewith or pursuant thereto, hereafter shall be deemed references to the Credit Agreement, as amended hereby. 

4.3 Except as amended hereby, the Credit Agreement and the other Related Documents shall in all respects continue in full force and
effect. 
 4.4 Capitalized terms used but not defined herein shall have the respective meanings ascribed thereto in the Credit
Agreement. 
 4.5 This Amendment shall be governed by and construed in accordance with the laws of the State of Michigan.

 4.6 The Borrower agrees to pay the reasonable fees and expenses of Dickinson Wright PLLC, counsel for the Bank, in connection
with the negotiation and preparation of this Amendment and the documents referred to herein and the consummation of the transactions contemplated hereby. Notwithstanding anything to the contrary, with respect only to the negotiation, preparation and
execution of this Amendment and the documents referred to in this Amendment and the consummation of the transactions contemplated by this Amendment, the Borrower shall not be liable for attorneys’ fees of counsel for the Bank exceeding $5,000
in the aggregate. 
 4.7 This Amendment may be executed upon any number of counterparts with the same effect as if the
signatures thereto were upon the same instrument. 
 4.8 Each party hereto, after consulting or having had the opportunity to
consult with counsel, knowingly, voluntarily, and intentionally waives any right any of them may have to a trial by jury in any litigation based upon or arising out of this Amendment, or any agreement referenced herein or other related instrument or
agreement, or any of the transactions contemplated by this Amendment, or any course of conduct, dealing, statements (whether oral or written) or actions of any of them. None of the parties hereto shall seek to consolidate, by counterclaim or
otherwise, any such action in which a jury trial has been waived with any other action in which a jury trial cannot be or has not been waived. These provisions shall not be deemed to have been modified in any respect or relinquished by any party
hereto except by a written instrument executed by both of them. 

  
 [Second
Amendment to Credit Agreement – Neogen Corporation] 
 -4- 

 4.9 The Borrower agrees to execute any and all documents reasonably deemed necessary or
appropriate by the Bank to carry out the intent of, and/or to implement, this Amendment. 
 4.10 This Amendment constitutes the
entire understanding of the parties with respect to the subject matter hereof. This Amendment is binding on the parties hereto and their respective successors and assigns, and shall inure to the benefit of the parties hereto and their respective
successors and assigns. If any of the provisions of this Amendment are in conflict with any applicable statute or rule or law or otherwise unenforceable, such offending provisions shall be null and void only to the extent of such conflict or
unenforceability, but shall be deemed separate from and shall not invalidate any other provision of this Amendment. 
 4.11 No
course of dealing on the part of the Bank, nor any delay or failure on the part of the Bank in exercising any right, power or privilege hereunder shall operate as a waiver of such right, power or privilege or otherwise prejudice the Bank’s
rights and remedies hereunder or under any Related Document or any other agreement or instrument of the Borrower with or in favor of the Bank; nor shall any single or partial exercise thereof preclude any further exercise thereof or the exercise of
any other right, power or privilege. No right or remedy conferred upon or reserved to the Bank under this Amendment or under any Related Document or any other agreement or instrument of the Borrower with or in favor of the Bank is intended to be
exclusive of any other right or remedy, and every right and remedy shall be cumulative and in addition to every other right or remedy granted thereunder or now or hereafter existing under any applicable law. Every right and remedy granted by this
Amendment or under any Related Document or any other agreement or instrument of the Borrower with or in favor of the Bank or by applicable law to the Bank may be exercised from time to time and as often as may be deemed expedient by the Bank.

 [The remainder of this page intentionally left blank.] 

  
 [Second
Amendment to Credit Agreement – Neogen Corporation] 
 -5- 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and
delivered as of the day and year first-above written. 
  

			
	NEOGEN CORPORATION
		
	By:	 	 /s/ Steven. J. Quinlan

		 	      Steven J. Quinlan
		 	      Its: Vice President and Chief Financial Officer
	
	JPMORGAN CHASE BANK, N.A.
		
	By:	 	 /s/ Joshua M. Tudor

		 	      Joshua M. Tudor
		 	      Its: Vice President

  
 [Second
Amendment to Credit Agreement – Neogen Corporation] 
 -6-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}]]